The European Association of Nuclear Medicine (EANM) and the American Society of Nuclear Cardiology (ASNC) have released a "Cardiac Amyloidosis Practice Points" document.
The goal is to identify the critical components involved in performing technetium-99m (Tc-99m) 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) or Tc-99m hydroxymethylene diphosphonate (HMDP) imaging to evaluate cardiac transthyretin amyloidosis, according to the organizations. The practice points can be downloaded on the EANM's website.
